CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. ("Eton”) by providing its proprietary innovative hydrocortisone formulation (the "CROSSJECT Formulation”) to enter the hospital ...

Equities research analysts at HC Wainwright dropped their Q2 2025 earnings estimates for Eton Pharmaceuticals in a report ...

Investment analysts at B. Riley increased their Q1 2025 earnings estimates for shares of Eton Pharmaceuticals in a research ...

Analysts have set 12-month price targets for Eton Pharmaceuticals, revealing an average target of $24.4, a high estimate of $33.00, and a low estimate of $17.00. Marking an increase of 22.0%, the ...

Management to Hold Investor Day Conference Call Today at 10:00am ETReported record product revenue of $11.6 million in Q4 2024, an increase of ...

The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, ...

The prefecture of Auvergne-Rhône-Alpes announced earlier on January 10 the termination of Al Kindi primary school, middle school and high school, on allegations of “carrying out a project ...

“I had one real offer out of high school. I always say this, (Husky coach Danny Sprinkle) believed in me when no one really believed in me. I remember I was writing emails to schools trying to ...

The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four ...

ST. LOUIS, March 04, 2025 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded partnership with Eton Pharmaceuticals ...